Preliminary results of a randomized phase IIb double-blind 2x2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention.

被引:0
|
作者
Bonanni, B
Guerrieri-Gonzaga, A
Robertson, C
Serrano, D
Cazzaniga, M
Mora, S
Gulisano, M
Johansson, H
Galimberti, V
Intra, M
Latronico, A
Franchi, D
Pelosi, D
Decensi, A
机构
[1] European Inst Oncol, Milan, Italy
[2] Univ Strathclyde, Glasgow, Lanark, Scotland
[3] Osped San Bortolo, Vicenza, Italy
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:S168 / S169
页数:2
相关论文
共 50 条
  • [21] A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers
    Decensi, A
    Robertson, C
    Viale, G
    Pigatto, F
    Johansson, H
    Kisanga, ER
    Veronesi, P
    Torrisi, R
    Cazzaniga, M
    Mora, S
    Sandri, MT
    Pelosi, G
    Luini, A
    Goldhirsch, A
    Lien, EA
    Veronesi, U
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (11) : 779 - 790
  • [22] A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis
    Ashtari, F.
    Shaygannejad, V.
    Akbari, M.
    ACTA NEUROLOGICA SCANDINAVICA, 2008, 118 (05): : 301 - 305
  • [23] Associations between a polymorphic locus in the promoter region of the IGFBP-3 gene, circulating IGFs, mammographic breast density and survival in a 2x2 trial of low-dose tamoxifen and fenretinide in premenopausal women
    Macis, Debora
    Gandini, Sara
    Guerrieri-Gonzaga, Aliana
    Harriet, Johansson
    Serrano, Davide
    Cazzaniga, Massimiliano
    Lazzeroni, Matteo
    Aristarco, Valentina
    Mora, Serena
    Pizzamiglio, Maria
    Latronico, Antuono
    Gulisano, Marcella
    Bonanni, Bernardo
    De Censi, Andrea
    CANCER RESEARCH, 2011, 71
  • [24] DOUBLE-BLIND RANDOMIZED TRIAL OF VERY-LOW-DOSE WARFARIN FOR PREVENTION OF THROMBOEMBOLISM IN STAGE-IV BREAST-CANCER
    LEVINE, M
    HIRSH, J
    GENT, M
    ARNOLD, A
    WARR, D
    FALANGA, A
    SAMOSH, M
    BRAMWELL, V
    PRITCHARD, KI
    STEWART, D
    GOODWIN, P
    LANCET, 1994, 343 (8902): : 886 - 889
  • [25] Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL
    Howard, D. R.
    Munir, T.
    McParland, L.
    Rawstron, A. C.
    Milligan, D.
    Schuh, A.
    Hockaday, A.
    Allsup, D. J.
    Marshall, S.
    Duncombe, A. S.
    O'Dwyer, J. L.
    Smith, A. F.
    Longo, R.
    Varghese, A.
    Hillmen, P.
    LEUKEMIA, 2017, 31 (11) : 2416 - 2425
  • [26] Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL
    D R Howard
    T Munir
    L McParland
    A C Rawstron
    D Milligan
    A Schuh
    A Hockaday
    D J Allsup
    S Marshall
    A S Duncombe
    J L O'Dwyer
    A F Smith
    R Longo
    A Varghese
    P Hillmen
    Leukemia, 2017, 31 : 2416 - 2425
  • [27] First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial
    Wang, Zi-Xian
    Peng, Junjie
    Liang, Xinjun
    Cheng, Ying
    Deng, Yanhong
    Chen, Kehe
    Zhang, Mingjun
    Zhang, Jingdong
    Wang, Wei
    Cao, Bangwei
    Jin, Yongdong
    Sun, Meili
    Lin, Yuan
    Luo, Suxia
    Li, Zhen
    Yang, Liu
    Ke, Ying
    Yu, Haoyu
    Li, Jing
    Wang, Qingyu
    Zhu, Jun
    Wang, Feng
    Xu, Rui-Hua
    MED, 2024, 5 (09):
  • [28] Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Primary Results of a Randomized, 2 x 2 Factorial, Placebo-Controlled, Double-Blind Clinical Trial
    Gulati, Geeta
    Heck, Siri L.
    Hoffmann, Pavel
    Ree, Anne H.
    Schulz-Menger, Jeanette
    von Knobelsdorff-Brenkenhoff, Florian
    Steine, Kjetil
    Bratland, Ase
    Gravdehaug, Berit
    Rosjo, Helge
    Geisler, Juergen
    Omland, Torbjorn
    CIRCULATION, 2015, 132 (23) : 2274 - 2274
  • [29] ON THE EFFICACY OF LOW-DOSE PREDNISOLONE AND HEPARIN SODIUM IN THE PREVENTION OF INFUSION THROMBOPHLEBITIS - A DOUBLE-BLIND TRIAL
    DECOCK, C
    VERMEIJ, P
    STIJNEN, T
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1984, 6 (02) : 88 - 90
  • [30] A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial OfReldesemtivIn Patients With ALS
    Shefner, Jeremy M.
    Andrews, Jinsy A.
    Genge, Angela
    Jackson, Carlayne
    Lechtzin, Noah
    Miller, Timothy M.
    Cockroft, Bettina M.
    Meng, Lisa
    Wei, Jenny
    Wolff, Andrew A.
    Malik, Fady, I
    Bodkin, Cynthia
    Brooks, Benjamin R.
    Caress, James
    Dionne, Annie
    Fee, Dominic
    Goutman, Stephen A.
    Goyal, Namita A.
    Hardiman, Orla
    Hayat, Ghazala
    Heiman-Patterson, Terry
    Heitzman, Daragh
    Henderson, Robert D.
    Johnston, Wendy
    Karam, Chafic
    Kiernan, Matthew C.
    Kolb, Stephen J.
    Korngut, Lawrence
    Ladha, Shafeeq
    Matte, Genevieve
    Mora, Jesus S.
    Needham, Merrilee
    Oskarsson, Bjorn
    Pattee, Gary L.
    Pioro, Erik P.
    Pulley, Michael
    Quan, Dianna
    Rezania, Kourosh
    Schellenberg, Kerri L.
    Schultz, David
    Shoesmith, Christen
    Simmons, Zachary
    Statland, Jeffrey
    Sultan, Shumaila
    Swenson, Andrea
    Van den Berg, Leonard H.
    Tuan Vu
    Vucic, Steve
    Weiss, Michael
    Whyte-Rayson, Ashley
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2021, 22 (3-4) : 287 - 299